Articles published by Rayzebio, Inc.

Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio

December 26, 2023

From Rayzebio, Inc.

Via GlobeNewswire

Tickers BMY RYZB

RayzeBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 13, 2023

From Rayzebio, Inc.

Via GlobeNewswire

Tickers RYZB

RayzeBio to Participate in Upcoming Investor Conferences in November 2023

November 06, 2023

From Rayzebio, Inc.

Via GlobeNewswire

Tickers RYZB

RayzeBio Appoints Industry Leader Tim Van Hauwermeiren to Its Board of Directors

November 01, 2023

From Rayzebio, Inc.

Via GlobeNewswire

Tickers RYZB

FDA selects RayzeBio to Participate in the Inaugural CDRP Program to Expedite Commercial Manufacturing Readiness for RYZ101 in GEP-NETs

October 24, 2023

From Rayzebio, Inc.

Via GlobeNewswire

Tickers RYZB

RayzeBio to Present at European Society for Medical Oncology (ESMO) Congress

October 18, 2023

From Rayzebio, Inc.

Via GlobeNewswire

Tickers RYZB

RayzeBio, Inc. Announces Closing of Upsized $358 Million Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

September 19, 2023

From RayzeBio, Inc.

Via Business Wire

Tickers RYZB

RayzeBio, Inc. Announces Pricing of Upsized $311 Million Initial Public Offering

September 14, 2023

From RayzeBio, Inc.

Via Business Wire

RayzeBio Appoints Christy Oliger to its Board of Directors

August 29, 2023

From RayzeBio, Inc.

Via Business Wire

RayzeBio to Present at Society of Nuclear Medicine and Molecular Imaging Annual Meeting

June 22, 2023

From RayzeBio, Inc.

Via Business Wire

RayzeBio Announces First Patient Dosed in Phase 3 ACTION-1 Study, Evaluating RYZ101 (Actinium-225 DOTATATE) in Neuroendocrine Tumors

May 31, 2023

From RayzeBio, Inc.

Via Business Wire

RayzeBio to Present at Upcoming Medical Conferences

May 22, 2023

From RayzeBio, Inc.

Via Business Wire

RayzeBio Nominates Glypican-3 (GPC3) Targeted Radiopharmaceutical Therapy Drug Candidate for Treatment of Liver Cancer

March 21, 2023

From RayzeBio, Inc.

Via Business Wire

RayzeBio Completes Phase 1b Enrollment in ACTION-1 Study, Evaluating RYZ101 (Actinium-225 DOTATATE) in Neuroendocrine Tumors

March 20, 2023

From RayzeBio, Inc.

Via Business Wire

RayzeBio Announces Issuance of Two Patents for RYZ101 (225Ac-DOTATATE)

January 04, 2023

From RayzeBio, Inc.

Via Business Wire

RayzeBio to Present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023

January 04, 2023

From RayzeBio, Inc.

Via Business Wire

RayzeBio Appoints Industry Veteran Rich Heyman, Ph.D. as Chairman of Board of Directors

December 07, 2022

From RayzeBio, Inc.

Via Business Wire

RayzeBio to Present at Upcoming Investor Conferences in November 2022

November 14, 2022

From RayzeBio, Inc.

Via Business Wire

RayzeBio Propels Forward with $418 Million Raised Since Inception to Advance Targeted Radiopharmaceuticals for Cancer

September 13, 2022

From RayzeBio, Inc.

Via Business Wire

RayzeBio Advances RYZ101, a Targeted Radiopharmaceutical Delivering Actinium-225, into Clinical Development for Two Cancer Indications

September 13, 2022

From RayzeBio, Inc.

Via Business Wire

RayzeBio Appoints Angie You, Ph.D., to its Board of Directors

April 25, 2022

From RayzeBio, Inc.

Via Business Wire

RayzeBio Expands Leadership Team with Arvind Kush as Chief Financial Officer; and Aubrey Haddach, J.D., as General Counsel

January 24, 2022

From RayzeBio, Inc.

Via Business Wire

RayzeBio to Present at J.P. Morgan Healthcare Virtual Conference on Tuesday, January 11, 2022

January 06, 2022

From RayzeBio, Inc.

Via Business Wire

RayzeBio Appoints Mary Tagliaferri, M.D. to its Board of Directors and Expands Leadership Team with Rozalyn Littler as VP of Regulatory and Quality

October 12, 2021

From RayzeBio, Inc.

Via Business Wire

RayzeBio Expands Leadership Team With Susan Moran, M.D., as Chief Medical Officer; Kimberly Ma, M.S., as SVP of Clinical Operations; and Nicholas Smith, Ph.D., as SVP of Chemistry Innovation

August 31, 2021

From RayzeBio, Inc.

Via Business Wire

RayzeBio Secures $108 Million Series C Financing to Drive Forward Its Pipeline of Targeted Radiopharmaceuticals for Cancer

June 15, 2021

From RayzeBio, Inc.

Via Business Wire

RayzeBio Appoints Yi Larson to Its Board of Directors and Expands Team with Key Leadership Hires

April 21, 2021

From RayzeBio, Inc.

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.